BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12640983)

  • 21. Safety panel backs principle of gene-therapy trials.
    Check E
    Nature; 2002 Dec; 420(6916):595. PubMed ID: 12478252
    [No Abstract]   [Full Text] [Related]  

  • 22. Looking into the safety of AAV vectors.
    Kay MA; Nakai H
    Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952
    [No Abstract]   [Full Text] [Related]  

  • 23. Good news for gene therapy.
    Berns A
    N Engl J Med; 2004 Apr; 350(16):1679-80. PubMed ID: 15084702
    [No Abstract]   [Full Text] [Related]  

  • 24. Gene therapists hopeful as trials resume with childhood disease.
    Check E
    Nature; 2004 Jun; 429(6992):587. PubMed ID: 15190314
    [No Abstract]   [Full Text] [Related]  

  • 25. Risks and benefits of gene therapy.
    Noguchi P
    N Engl J Med; 2003 Jan; 348(3):193-4. PubMed ID: 12529458
    [No Abstract]   [Full Text] [Related]  

  • 26. Success and setback: another adverse event.
    Verma IM
    Mol Ther; 2002 Nov; 6(5):565-6. PubMed ID: 12409253
    [No Abstract]   [Full Text] [Related]  

  • 27. Too high a cost for a cure?
    Boyce N
    US News World Rep; 2002 Oct; 133(14):34. PubMed ID: 12389521
    [No Abstract]   [Full Text] [Related]  

  • 28. French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.
    European Society of Gene Therapy
    J Gene Med; 2003 Jan; 5(1):82-4. PubMed ID: 12516054
    [No Abstract]   [Full Text] [Related]  

  • 29. American Society of Gene Therapy meeting. Retroviral vectors: a double-edged sword.
    Kaiser J
    Science; 2005 Jun; 308(5729):1735-6. PubMed ID: 15961648
    [No Abstract]   [Full Text] [Related]  

  • 30. Gene-therapy trials to restart following cancer risk review.
    Check E
    Nature; 2005 Mar; 434(7030):127. PubMed ID: 15758959
    [No Abstract]   [Full Text] [Related]  

  • 31. Progress toward the genetic treatment of the beta-thalassemias.
    Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
    Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Occurrence of leukaemia following gene therapy of X-linked SCID.
    Kohn DB; Sadelain M; Glorioso JC
    Nat Rev Cancer; 2003 Jul; 3(7):477-88. PubMed ID: 12835668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Methodology of gene therapy: adverse events and further technological developments].
    Hamada H
    Nihon Rinsho; 2010 Aug; 68 Suppl 8():601-6. PubMed ID: 20979308
    [No Abstract]   [Full Text] [Related]  

  • 34. Serial transplantations in nonobese diabetic/severe combined immunodeficiency mice of transduced human CD34+ cord blood cells: efficient oncoretroviral gene transfer and ex vivo expansion under serum-free conditions.
    Gammaitoni L; Lucchi S; Bruno S; Tesio M; Gunetti M; Pignochino Y; Migliardi G; Lazzari L; Aglietta M; Rebulla P; Piacibello W
    Stem Cells; 2006 May; 24(5):1201-12. PubMed ID: 16410386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
    Kang EM; Tisdale JF
    Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene therapy. Panel urges limits on X-SCID trials.
    Kaiser J
    Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
    [No Abstract]   [Full Text] [Related]  

  • 37. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.
    Hacein-Bey-Abina S; von Kalle C; Schmidt M; Le Deist F; Wulffraat N; McIntyre E; Radford I; Villeval JL; Fraser CC; Cavazzana-Calvo M; Fischer A
    N Engl J Med; 2003 Jan; 348(3):255-6. PubMed ID: 12529469
    [No Abstract]   [Full Text] [Related]  

  • 38. Gene therapy for human severe combined immunodeficiencies.
    Fischer A; Hacein-Bey S; Le Deist F; de Saint Basile G; Cavazzana-Calvo M
    Isr Med Assoc J; 2002 Jan; 4(1):51-4. PubMed ID: 11802313
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapy on trial.
    Hughes V
    Nat Med; 2007 Sep; 13(9):1008-9. PubMed ID: 17828211
    [No Abstract]   [Full Text] [Related]  

  • 40. Harmful potential of viral vectors fuels doubts over gene therapy.
    Check E
    Nature; 2003 Jun; 423(6940):573-4. PubMed ID: 12789298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.